Oxford Instruments reports strong results, sells quantum business

Oxford Instruments (OXIG) reported annual revenue exceeding £500 million for the first time, up 6.5% organically, with adjusted operating profit rising 10.8% to £82.2 million driven by strength in semiconductor and materials analysis offsetting weakness in healthcare. The company announced the sale of its NanoScience quantum business for £60 million to focus on higher-growth areas and a £50 million share buyback program, funded in part by the sale, reflecting confidence in its financial position and commitment to shareholder returns; the board also proposed a 6.7% dividend increase.

Analysis

Oxford Instruments plc (OXIG) reported a robust fiscal year ending March 31, 2025, achieving a significant milestone as annual revenue surpassed £500 million for the first time, reaching £500.6 million, a 6.5% increase on an organic constant currency basis from £470.4 million in the prior year. This top-line growth was complemented by a 10.8% rise in adjusted operating profit to £82.2 million, expanding the operating profit margin by 70 basis points to 17.8%. The company's performance was notably bolstered by strong results in its semiconductor and materials analysis segments, which effectively offset ongoing weakness within the healthcare and life science markets. A key driver for this growth was an increase in revenue from commercial customers, which now constitutes approximately 50% of total revenue, up from 45% previously. Strategically, Oxford Instruments is divesting its NanoScience quantum business for £60 million to sharpen its focus on businesses offering stronger growth and margin characteristics. This financial strength, evidenced by a net cash position of £84.4 million and an improved cash conversion rate of 89%, supports a £50 million share buyback program and a proposed 6.7% increase in the total dividend to 22.2 pence per share, signaling management's confidence and commitment to enhancing shareholder value.

Key Decisions for Investors

• Consider the positive implications of Oxford Instruments' record revenue, enhanced profitability, and strategic divestment aimed at concentrating on higher-growth, higher-margin segments.
• Evaluate the potential for increased shareholder returns stemming from the announced £50 million share buyback program and the 6.7% proposed dividend increase, supported by a solid net cash position and improved cash conversion.
• Monitor the company's progress in integrating the strategic shift away from the quantum business, the sustained performance of its semiconductor and materials analysis divisions, and any developments in the weaker healthcare and life science markets.